Literature DB >> 24061772

Paternal bone marrow infusion as salvage therapy for severe GVHD following maternal haploidentical transplantation resulting in biparental chimerism.

Sarita Rani Jaiswal1, Sumita Chatterjee, Suparno Chakrabarti.   

Abstract

We describe a case of severe GVHD in a 3-year-old child who had received a maternal haploidentical allograft for thalassemia major, which was refractory to several lines of therapy, including weekly infusion of mesenchymal cells. The child was infused paternal marrow graft from which T cells were depleted using Campath 'in the bag' without conditioning. There was significant improvement in gut and liver GVHD over the next few weeks along with persistent mixed biparental chimerism before the child succumbed to CMV pneumonitis. This approach hints at the possibility of using parental TCD marrow to salvage GVHD caused by a graft from the other parent, and raises the possibility of biparental grafting along the same lines as double cord transplantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24061772     DOI: 10.1007/s12185-013-1426-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Second allo-SCT from a different donor can improve severe steroid-resistant gut GVHD.

Authors:  C Ustun; A Jillella; R Shah; K Sterling; D Deremer; N Savage; F Awan; J R Gossage; T Dillard; P J Martin
Journal:  Bone Marrow Transplant       Date:  2010-02-22       Impact factor: 5.483

2.  T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.

Authors:  Suparno Chakrabarti; Dorothy MacDonald; Geoff Hale; Kathleen Holder; Virginia Turner; Halina Czarnecka; Jacqui Thompson; Christopher Fegan; Herman Waldmann; Donald W Milligan
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

Review 3.  Treatment of graft-versus-host-disease with mesenchymal stromal cells.

Authors:  Partow Kebriaei; Simon Robinson
Journal:  Cytotherapy       Date:  2011-01-13       Impact factor: 5.414

4.  Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.

Authors:  Kazuhiro Ikegame; Satoshi Yoshihara; Yuki Taniguchi; Katsuji Kaida; Takayuki Inoue; Masaya Okada; Kyoko Taniguchi; Hitomi Hasei; Hiroya Tamaki; Tatsuya Fujioka; Ruri Kato; Toshihiro Soma; Hiroyasu Ogawa
Journal:  Exp Hematol       Date:  2011-05-27       Impact factor: 3.084

5.  Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin.

Authors:  Maria Teresa Van Lint; Giuseppe Milone; Salvatore Leotta; Cornelio Uderzo; Rosanna Scimè; Sandro Dallorso; Anna Locasciulli; Stefano Guidi; Nicola Mordini; Simona Sica; Laura Cudillo; Franca Fagioli; Carmine Selleri; Barbara Bruno; William Arcese; Andrea Bacigalupo
Journal:  Blood       Date:  2006-01-31       Impact factor: 22.113

6.  Autologous/syngeneic stem cell transplantation to treat refractory GvHD.

Authors:  J R Passweg; K Orchard; A Buergi; A Gratwohl; R Powles; J Goldman; J Apperley; J Mehta
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

7.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

Authors:  Michael R Verneris; Claudio G Brunstein; Juliet Barker; Margaret L MacMillan; Todd DeFor; David H McKenna; Michael J Burke; Bruce R Blazar; Jeffrey S Miller; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Blood       Date:  2009-08-25       Impact factor: 22.113

8.  Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.

Authors:  Yuki Taniguchi; Satoshi Yoshihara; Yoshihiko Hoshida; Takayuki Inoue; Tatsuya Fujioka; Kazuhiro Ikegame; Manabu Kawakami; Tomoki Masuda; Katsuyuki Aozasa; Ichiro Kawase; Hiroyasu Ogawa
Journal:  Exp Hematol       Date:  2008-07-02       Impact factor: 3.084

9.  Double haploidentical hematopoietic stem cell transplantation results in successful engraftment of bone marrow from both donors without graft-versus-host or graft-versus-graft effects.

Authors:  Chandra S Biswas; Christopher T Sauter; Cavan P Bailey; Daniel Rittenberg; Xiaoling Luo; Michelle M Panis; Tulin Budak-Alpdogan; Dolores Grosso; Neal Flomenberg; Onder Alpdogan
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-16       Impact factor: 5.742

10.  Tolerance to histocompatibility determinants in tetraparental bone marrow chimeras.

Authors:  H Boehmer; J Sprent; M Nabholz
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

View more
  1 in total

1.  Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide.

Authors:  Sarita Rani Jaiswal; Aditi Chakrabarti; Sumita Chatterjee; Sneh Bhargava; Kunal Ray; Suparno Chakrabarti
Journal:  Int J Hematol       Date:  2015-11-30       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.